Latest news and press releases about Belite Bio, Inc (BLTE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily.
Price
| Price | $169.21 |
| Market Cap | $6.8B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 8.75 |
| EV / EBITDA | -64.97 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -10.07% |
| Return on Invested Capital | -10.92% |
| Return on Assets | -9.94% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACAD · ADMA · ARQT · CRNX · DYN · LGND · MIRM
Explore sector: Healthcare · Biotechnology
More sections of BLTE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks